The listed company Sonnet will merge to form Hyperliquid Strategies and launch a cryptocurrency fund strategy, holding 12.6 million HYPE and 300 million dollars in cash
ChainCatcher news, according to The Block, Nasdaq-listed Sonnet BioTherapeutics has agreed to an $888 million merger deal, will be renamed Hyperliquid Strategies, and will launch the HYPE treasury strategy.The Nasdaq-listed Sonnet BioTherapeutics has agreed to merge with Rorschach I LLC to form Hyperliquid Strategies and initiate the treasury strategy. According to a press release issued on Monday, Rorschach I LLC is a newly formed company associated with Atlas Merchant Capital LLC, Paradigm Operations LP, and other sponsors.Upon completion of the transaction, the new entity will be renamed Hyperliquid Strategies and is expected to hold 12.6 million HYPE tokens and $305 million in cash, with a total valuation of approximately $888 million. The deal has strategic investors including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. After the merger is completed, Hyperliquid Strategies will continue to trade on Nasdaq, with a change in stock ticker, becoming a publicly listed cryptocurrency treasury company.The parties involved in the transaction stated that the cash proceeds will enable Hyperliquid Strategies to increase its holdings of HYPE tokens and build a top-tier HYPE strategic treasury. After the transaction is completed, Atlas co-founder and CEO Bob Diamond will serve as chairman of Hyperliquid Strategies, while another Atlas co-founder and CIO David Schamis will take on the role of CEO.